BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gorbet MJ, Ranjan A. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. Pharmacol Ther 2020;207:107456. [PMID: 31863820 DOI: 10.1016/j.pharmthera.2019.107456] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Jia Y, Wang X, Deng Y, Li S, Xu X, Qin Y, Peng L. Pyroptosis Provides New Strategies for the Treatment of Cancer. J Cancer 2023;14:140-51. [PMID: 36605484 DOI: 10.7150/jca.77965] [Reference Citation Analysis]
2 Panjwani D, Mishra D, Patel S, Patel V, Dharamsi A, Patel A. A Perspective on EGFR and Proteasome-based Targeted Therapy for Cancer. Curr Drug Targets 2022;23:1406-17. [PMID: 36089785 DOI: 10.2174/1389450123666220908095121] [Reference Citation Analysis]
3 Comanescu C. Magnetic Nanoparticles: Current Advances in Nanomedicine, Drug Delivery and MRI. Chemistry 2022;4:872-930. [DOI: 10.3390/chemistry4030063] [Reference Citation Analysis]
4 Mussafi O, Mei J, Mao W, Wan Y. Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. Front Oncol 2022;12:948405. [DOI: 10.3389/fonc.2022.948405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tu Y, Yao Z, Yang W, Tao S, Li B, Wang Y, Su Z, Li S. Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine. Front Nanotechnol 2022;4. [DOI: 10.3389/fnano.2022.948705] [Reference Citation Analysis]
6 Chan LP, Tseng YP, Wang HC, Chien CY, Wu CW, Wang LF, Liang CH. Growth regulated oncogene-α contribute to EMT/MMPs pathway by binding its receptors in head and neck squamous cell carcinoma. Life Sci 2022;306:120791. [PMID: 35817169 DOI: 10.1016/j.lfs.2022.120791] [Reference Citation Analysis]
7 Nirmala JG, Meher K, Lopus M. Proteomic and metabolomic profiling combined with in vitro studies reveal the antiproliferative mechanism of silver nanoparticles in MDA-MB-231 breast carcinoma cells. J Mater Chem B 2022. [PMID: 35262119 DOI: 10.1039/d1tb02760c] [Reference Citation Analysis]
8 Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PCW, Jin JO. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Semin Cancer Biol 2022:S1044-579X(22)00044-X. [PMID: 35181474 DOI: 10.1016/j.semcancer.2022.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 C de S L Oliveira AL, Schomann T, de Geus-Oei LF, Kapiteijn E, Cruz LJ, de Araújo Junior RF. Nanocarriers as a Tool for the Treatment of Colorectal Cancer. Pharmaceutics 2021;13:1321. [PMID: 34452282 DOI: 10.3390/pharmaceutics13081321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. ACS Nano 2021. [PMID: 34339170 DOI: 10.1021/acsnano.1c02103] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 17.0] [Reference Citation Analysis]
11 Chung S, Revia RA, Zhang M. Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy. Nanoscale Horiz 2021;6:696-717. [PMID: 34286791 DOI: 10.1039/d1nh00179e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
12 Zhang LY, Yang X, Wang SB, Chen H, Pan HY, Hu ZM. Membrane Derived Vesicles as Biomimetic Carriers for Targeted Drug Delivery System. Curr Top Med Chem 2020;20:2472-92. [PMID: 32962615 DOI: 10.2174/1568026620666200922113054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
13 Ram Kumar PS, Rencilin CF, Sundar K. Emerging nanomaterials for cancer immunotherapy. Exploration of Medicine 2021;2:208-31. [DOI: 10.37349/emed.2021.00043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zuo S, Song J, Zhang J, He Z, Sun B, Sun J. Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what? Theranostics 2021;11:7471-87. [PMID: 34158861 DOI: 10.7150/thno.59953] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
15 Silveira MJ, Castro F, Oliveira MJ, Sarmento B. Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored? Biomater Sci 2021;9:3228-43. [PMID: 33949441 DOI: 10.1039/d1bm00137j] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Chauhan DS, Dhasmana A, Laskar P, Prasad R, Jain NK, Srivastava R, Jaggi M, Chauhan SC, Yallapu MM. Nanotechnology synergized immunoengineering for cancer. Eur J Pharm Biopharm 2021;163:72-101. [PMID: 33774162 DOI: 10.1016/j.ejpb.2021.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tan B, Tang Q, Zhong Y, Wei Y, He L, Wu Y, Wu J, Liao J. Biomaterial-based strategies for maxillofacial tumour therapy and bone defect regeneration. Int J Oral Sci 2021;13:9. [PMID: 33727527 DOI: 10.1038/s41368-021-00113-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 19.5] [Reference Citation Analysis]
18 Khan A, Dias F, Neekhra S, Singh B, Srivastava R. Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics. Front Chem 2020;8:631351. [PMID: 33585406 DOI: 10.3389/fchem.2020.631351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson ML. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. Future Oncol 2021;17:1401-39. [PMID: 33475012 DOI: 10.2217/fon-2020-0967] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Padmanabhan R, Meskin N, Moustafa AA. Immunotherapy Models. Series in BioEngineering 2021. [DOI: 10.1007/978-981-15-8640-8_4] [Reference Citation Analysis]
21 Chang M, Hou Z, Wang M, Li C, Lin J. Recent Advances in Hyperthermia Therapy-Based Synergistic Immunotherapy. Adv Mater 2021;33:e2004788. [PMID: 33289219 DOI: 10.1002/adma.202004788] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 44.0] [Reference Citation Analysis]
22 Gherasim O, Puiu RA, Bîrcă AC, Burdușel AC, Grumezescu AM. An Updated Review on Silver Nanoparticles in Biomedicine. Nanomaterials (Basel) 2020;10:E2318. [PMID: 33238486 DOI: 10.3390/nano10112318] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 18.3] [Reference Citation Analysis]
23 Banstola A, Jeong JH, Yook S. Immunoadjuvants for cancer immunotherapy: A review of recent developments. Acta Biomater 2020;114:16-30. [PMID: 32777293 DOI: 10.1016/j.actbio.2020.07.063] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
24 Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol 2020;10:1672. [PMID: 33014834 DOI: 10.3389/fonc.2020.01672] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
25 Sethuraman SN, Singh MP, Patil G, Li S, Fiering S, Hoopes PJ, Guha C, Malayer J, Ranjan A. Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity. Theranostics 2020;10:3397-412. [PMID: 32206098 DOI: 10.7150/thno.42243] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]